B-Cell Responses in Hospitalized Severe Acute Respiratory Syndrome Coronavirus 2-Infected Children With and Without Multisystem Inflammatory Syndrome.
COVID-19
antibody avidity
antibody-secreting cells
antiviral antibody
flow cytometry
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
13 09 2022
13 09 2022
Historique:
received:
11
02
2022
accepted:
15
04
2022
pubmed:
19
4
2022
medline:
16
9
2022
entrez:
18
4
2022
Statut:
ppublish
Résumé
Multisystem inflammatory syndrome in children (MIS-C) can complicate infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but differences in the immune responses during MIS-C compared to coronavirus disease 2019 (COVID-19) are poorly understood. We longitudinally compared the amounts and avidity of plasma anti-nucleocapsid (N) and spike (S) antibodies, phenotypes of B cells, and numbers of virus-specific antibody-secreting cells in circulation of children hospitalized with COVID-19 (n = 10) and with MIS-C (n = 12). N-specific immunoglobulin G (IgG) was higher early after presentation for MIS-C than COVID-19 patients and avidity of N- and S-specific IgG at presentation did not mature further during follow-up as it did for COVID-19. Both groups had waning proportions of B cells in circulation and decreasing but sustained production of virus-specific antibody-secreting cells for months. Overall, B-cell responses were similar, but those with MIS-C demonstrated a more mature antibody response at presentation compared to COVID-19, suggesting a postinfectious entity.
Identifiants
pubmed: 35436340
pii: 6569992
doi: 10.1093/infdis/jiac119
pmc: PMC9047220
doi:
Substances chimiques
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
822-832Subventions
Organisme : NIAID NIH HHS
ID : T32 AI052071
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. D. G. is on advisory boards for GlaxoSmithKline, Takeda Pharmaceutical, and GreenLight Biosciences. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Med. 2021 Mar;27(3):454-462
pubmed: 33589825
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
J Infect Dis. 2010 Dec 1;202(11):1659-66
pubmed: 20979459
PLoS Biol. 2018 Aug 10;16(8):e2006601
pubmed: 30096134
Cell. 2020 Nov 12;183(4):982-995.e14
pubmed: 32991843
Curr Opin Immunol. 2017 Apr;45:119-125
pubmed: 28355576
Nat Commun. 2020 Nov 27;11(1):6044
pubmed: 33247152
Emerg Infect Dis. 2007 Oct;13(10):1562-4
pubmed: 18258008
Viral Immunol. 2022 Apr;35(3):259-272
pubmed: 35285743
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
J Immunol. 2011 Jun 15;186(12):7264-8
pubmed: 21576510
Emerg Infect Dis. 2016 Jun;22(6):
pubmed: 27192543
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Microbes Infect. 2005 May;7(5-6):882-9
pubmed: 15878679
Clin Infect Dis. 2021 Jan 27;72(2):301-308
pubmed: 33501951
JCI Insight. 2020 Feb 13;5(3):
pubmed: 31935196
J Infect Dis. 2006 Mar 15;193(6):792-5
pubmed: 16479513
J Med Virol. 2006 Nov;78(11):1493-7
pubmed: 16998887
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Immunol Rev. 2003 Aug;194:8-18
pubmed: 12846803
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Infect Dis. 2021 Aug 16;224(4):606-615
pubmed: 34398245
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
J Infect Dis. 1991 Apr;163(4):693-8
pubmed: 2010624
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
JAMA. 2020 Jul 21;324(3):246-248
pubmed: 32511667
Curr Gene Ther. 2016;16(3):156-67
pubmed: 27216914
Annu Rev Immunol. 2012;30:429-57
pubmed: 22224772
Ann Rheum Dis. 2020 Aug;79(8):999-1006
pubmed: 32527868
Immunity. 2016 Sep 20;45(3):471-482
pubmed: 27653600
J Virol. 1995 Mar;69(3):1895-902
pubmed: 7853531
Sci Immunol. 2021 Mar 2;6(57):
pubmed: 33653907
Immunity. 2021 May 11;54(5):1083-1095.e7
pubmed: 33891889
Clin Exp Immunol. 1981 Oct;46(1):1-8
pubmed: 7039877
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
JAMA. 2021 Mar 16;325(11):1074-1087
pubmed: 33625505
Nat Med. 2020 Nov;26(11):1701-1707
pubmed: 32812012
Curr Opin Immunol. 2017 Apr;45:97-102
pubmed: 28319733
J Infect Dis. 2009 Oct 1;200(7):1031-8
pubmed: 19702505
Influenza Other Respir Viruses. 2019 May;13(3):226-232
pubmed: 30770641
Clin Infect Dis. 2022 Jan 29;74(2):254-262
pubmed: 34013339